Company Overview
About BostonGene
BostonGene is a biomedical company founded in 2015 that applies artificial intelligence and next-generation sequencing to decode cancer patients' molecular profiles, enabling oncologists and biopharma researchers to make more precise treatment decisions. Its AI-powered multiomics platform analyzes tumor microenvironments, genomic drivers, and immune system interactions to identify the most effective therapy for each patient, reducing trial-and-error in cancer treatment selection.
Business Model & Competitive Advantage
The company serves both clinical and biopharma customers. For healthcare providers, BostonGene generates comprehensive molecular profiling reports that guide oncology decisions across hematologic and solid tumor cancers. For biopharma partners, it provides AI-driven biomarker discovery, patient stratification, and real-time clinical trial monitoring. In March 2025, BostonGene announced a strategic collaboration with Johnson & Johnson to evaluate biomarkers for colorectal cancer and multiple myeloma using its AI-driven platform.
Competitive Landscape 2025–2026
BostonGene received Frost & Sullivan's 2025 Global Technology Innovation Leadership Award in AI-driven Precision Oncology Solutions and was named BioTech Breakthrough's 2025 Overall Immunology Company of the Year. The company has also been recognized by GlobalData as a leading innovator in AI-driven drug repurposing. With growing adoption among oncology centers and major pharma collaborations, BostonGene is establishing itself as a central infrastructure provider for the next generation of precision cancer medicine.
Key Differentiators
Strong Challenger
BostonGene is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
Karius
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Compare BostonGene with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from BostonGene? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim BostonGene Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention BostonGene vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →